source
- Rocket Pharmaceuticals sells pediatric disease priority review voucher for $180 million; Oruka eyes $500 million offeringRocket Pharmaceuticals, a New Jersey gene-therapy company, sold its priority review voucher for a rare pediatric disease to an undisclosed buyer for $180 million. The voucher was earned after the…
- Google’s clinical director discusses AI challenges in health care in STAT Health Tech newsletterSTAT Health Tech newsletter featured an interview with Google’s clinical director, focusing on the practical challenges of deploying artificial intelligence in health care settings. The discussion…